Loading…

Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway

To evaluate the protective effect of nebivolol against kidney damage and elucidate the underlying mechanism in a two-kidney, one-clip (2K1C) rat model. 2K1C rats were obtained by clipping left renal artery of male Wistar rats and were considered hypertensive when systolic blood pressure (SBP) was ≥1...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2018-09, Vol.70 (5), p.917
Main Authors: Wang, Yan, Niu, Mengzhen, Yin, Sha, Zhang, Fei, Shi, Ruizan
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 5
container_start_page 917
container_title Pharmacological reports
container_volume 70
creator Wang, Yan
Niu, Mengzhen
Yin, Sha
Zhang, Fei
Shi, Ruizan
description To evaluate the protective effect of nebivolol against kidney damage and elucidate the underlying mechanism in a two-kidney, one-clip (2K1C) rat model. 2K1C rats were obtained by clipping left renal artery of male Wistar rats and were considered hypertensive when systolic blood pressure (SBP) was ≥160 mmHg 4 weeks after surgery. The 2K1C hypertensive rats were divided into untreated, nebivolol (10 mg/kg, ig), and atenolol (80 mg/kg, ig) treatment groups. The treatments lasted for 8 weeks. SBP, kidney structure and function, plasma and kidney angiotensin (Ang) II, nitric oxide (NO), asymmetric dimethylarginine (ADMA), and the oxidant status were examined. Kidney protein expression of NADPH oxidase (Nox) isoforms and its subunit p22 , nitric oxide synthase (NOS) isoforms, protein arginine N-methyltransferase (PRMT) 1, and dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 was tested by western blotting. Nebivolol and atenolol exerted similar hypotensive effects. However, atenolol had little effect while nebivolol significantly ameliorated the functional decline and structural damage in the kidney, especially in non-clipped kidney (NCK), which was associated with the reduction of Ang II in NCK. Moreover, nebivolol inhibited the NCK production of reactive oxygen species (ROS) by decreasing Nox2, Nox4, and p22 expression. Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression. Nebivolol also increased the NCK NO level by ameliorating the expression of kidney NOS isoforms. Our results demonstrated that long-term treatment with nebivolol had renoprotective effect in 2K1C rats partly via regulation of kidney ROS-ADMA-NO pathway.
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_32002962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32002962</sourcerecordid><originalsourceid>FETCH-pubmed_primary_320029623</originalsourceid><addsrcrecordid>eNqFjs0KgkAUhWdRZH-vEPcFhJnRipZiRRAVVHsZ86pT6gzjWPj2GdS61fngfAdOjwzZ0vNdxnzqkFFd3yn1GffmA-J4nFK-WvAhyY6oc6O0URZvVj4RME07qkGlUGEsn6pQBcgK-J6FYETX2G7QZDkYzJpCWKmqj2xzhIdMKmzhfLq4wfoQuMcTaGHzl2gnpJ-KosbpN8dktt1cw52rm7jEJNJGlsK00e-Z91d4A7rHQ5g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway</title><source>ScienceDirect</source><source>Springer Link</source><creator>Wang, Yan ; Niu, Mengzhen ; Yin, Sha ; Zhang, Fei ; Shi, Ruizan</creator><creatorcontrib>Wang, Yan ; Niu, Mengzhen ; Yin, Sha ; Zhang, Fei ; Shi, Ruizan</creatorcontrib><description>To evaluate the protective effect of nebivolol against kidney damage and elucidate the underlying mechanism in a two-kidney, one-clip (2K1C) rat model. 2K1C rats were obtained by clipping left renal artery of male Wistar rats and were considered hypertensive when systolic blood pressure (SBP) was ≥160 mmHg 4 weeks after surgery. The 2K1C hypertensive rats were divided into untreated, nebivolol (10 mg/kg, ig), and atenolol (80 mg/kg, ig) treatment groups. The treatments lasted for 8 weeks. SBP, kidney structure and function, plasma and kidney angiotensin (Ang) II, nitric oxide (NO), asymmetric dimethylarginine (ADMA), and the oxidant status were examined. Kidney protein expression of NADPH oxidase (Nox) isoforms and its subunit p22 , nitric oxide synthase (NOS) isoforms, protein arginine N-methyltransferase (PRMT) 1, and dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 was tested by western blotting. Nebivolol and atenolol exerted similar hypotensive effects. However, atenolol had little effect while nebivolol significantly ameliorated the functional decline and structural damage in the kidney, especially in non-clipped kidney (NCK), which was associated with the reduction of Ang II in NCK. Moreover, nebivolol inhibited the NCK production of reactive oxygen species (ROS) by decreasing Nox2, Nox4, and p22 expression. Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression. Nebivolol also increased the NCK NO level by ameliorating the expression of kidney NOS isoforms. Our results demonstrated that long-term treatment with nebivolol had renoprotective effect in 2K1C rats partly via regulation of kidney ROS-ADMA-NO pathway.</description><identifier>ISSN: 1734-1140</identifier><identifier>PMID: 32002962</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Animals ; Antihypertensive Agents - pharmacology ; Arginine - analogs &amp; derivatives ; Arginine - metabolism ; Gene Expression Regulation - drug effects ; Hypertension - etiology ; Isoenzymes ; Kidney - drug effects ; Kidney Diseases - prevention &amp; control ; Male ; Nebivolol - pharmacology ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - genetics ; Nitric Oxide Synthase - metabolism ; Podocytes - drug effects ; Podocytes - pathology ; Rats ; Rats, Wistar ; Reactive Oxygen Species - metabolism</subject><ispartof>Pharmacological reports, 2018-09, Vol.70 (5), p.917</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32002962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Niu, Mengzhen</creatorcontrib><creatorcontrib>Yin, Sha</creatorcontrib><creatorcontrib>Zhang, Fei</creatorcontrib><creatorcontrib>Shi, Ruizan</creatorcontrib><title>Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway</title><title>Pharmacological reports</title><addtitle>Pharmacol Rep</addtitle><description>To evaluate the protective effect of nebivolol against kidney damage and elucidate the underlying mechanism in a two-kidney, one-clip (2K1C) rat model. 2K1C rats were obtained by clipping left renal artery of male Wistar rats and were considered hypertensive when systolic blood pressure (SBP) was ≥160 mmHg 4 weeks after surgery. The 2K1C hypertensive rats were divided into untreated, nebivolol (10 mg/kg, ig), and atenolol (80 mg/kg, ig) treatment groups. The treatments lasted for 8 weeks. SBP, kidney structure and function, plasma and kidney angiotensin (Ang) II, nitric oxide (NO), asymmetric dimethylarginine (ADMA), and the oxidant status were examined. Kidney protein expression of NADPH oxidase (Nox) isoforms and its subunit p22 , nitric oxide synthase (NOS) isoforms, protein arginine N-methyltransferase (PRMT) 1, and dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 was tested by western blotting. Nebivolol and atenolol exerted similar hypotensive effects. However, atenolol had little effect while nebivolol significantly ameliorated the functional decline and structural damage in the kidney, especially in non-clipped kidney (NCK), which was associated with the reduction of Ang II in NCK. Moreover, nebivolol inhibited the NCK production of reactive oxygen species (ROS) by decreasing Nox2, Nox4, and p22 expression. Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression. Nebivolol also increased the NCK NO level by ameliorating the expression of kidney NOS isoforms. Our results demonstrated that long-term treatment with nebivolol had renoprotective effect in 2K1C rats partly via regulation of kidney ROS-ADMA-NO pathway.</description><subject>Animals</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Arginine - analogs &amp; derivatives</subject><subject>Arginine - metabolism</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Hypertension - etiology</subject><subject>Isoenzymes</subject><subject>Kidney - drug effects</subject><subject>Kidney Diseases - prevention &amp; control</subject><subject>Male</subject><subject>Nebivolol - pharmacology</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - genetics</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Podocytes - drug effects</subject><subject>Podocytes - pathology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reactive Oxygen Species - metabolism</subject><issn>1734-1140</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFjs0KgkAUhWdRZH-vEPcFhJnRipZiRRAVVHsZ86pT6gzjWPj2GdS61fngfAdOjwzZ0vNdxnzqkFFd3yn1GffmA-J4nFK-WvAhyY6oc6O0URZvVj4RME07qkGlUGEsn6pQBcgK-J6FYETX2G7QZDkYzJpCWKmqj2xzhIdMKmzhfLq4wfoQuMcTaGHzl2gnpJ-KosbpN8dktt1cw52rm7jEJNJGlsK00e-Z91d4A7rHQ5g</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Wang, Yan</creator><creator>Niu, Mengzhen</creator><creator>Yin, Sha</creator><creator>Zhang, Fei</creator><creator>Shi, Ruizan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201809</creationdate><title>Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway</title><author>Wang, Yan ; Niu, Mengzhen ; Yin, Sha ; Zhang, Fei ; Shi, Ruizan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_320029623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Arginine - analogs &amp; derivatives</topic><topic>Arginine - metabolism</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Hypertension - etiology</topic><topic>Isoenzymes</topic><topic>Kidney - drug effects</topic><topic>Kidney Diseases - prevention &amp; control</topic><topic>Male</topic><topic>Nebivolol - pharmacology</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - genetics</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Podocytes - drug effects</topic><topic>Podocytes - pathology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reactive Oxygen Species - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Niu, Mengzhen</creatorcontrib><creatorcontrib>Yin, Sha</creatorcontrib><creatorcontrib>Zhang, Fei</creatorcontrib><creatorcontrib>Shi, Ruizan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yan</au><au>Niu, Mengzhen</au><au>Yin, Sha</au><au>Zhang, Fei</au><au>Shi, Ruizan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway</atitle><jtitle>Pharmacological reports</jtitle><addtitle>Pharmacol Rep</addtitle><date>2018-09</date><risdate>2018</risdate><volume>70</volume><issue>5</issue><spage>917</spage><pages>917-</pages><issn>1734-1140</issn><abstract>To evaluate the protective effect of nebivolol against kidney damage and elucidate the underlying mechanism in a two-kidney, one-clip (2K1C) rat model. 2K1C rats were obtained by clipping left renal artery of male Wistar rats and were considered hypertensive when systolic blood pressure (SBP) was ≥160 mmHg 4 weeks after surgery. The 2K1C hypertensive rats were divided into untreated, nebivolol (10 mg/kg, ig), and atenolol (80 mg/kg, ig) treatment groups. The treatments lasted for 8 weeks. SBP, kidney structure and function, plasma and kidney angiotensin (Ang) II, nitric oxide (NO), asymmetric dimethylarginine (ADMA), and the oxidant status were examined. Kidney protein expression of NADPH oxidase (Nox) isoforms and its subunit p22 , nitric oxide synthase (NOS) isoforms, protein arginine N-methyltransferase (PRMT) 1, and dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 was tested by western blotting. Nebivolol and atenolol exerted similar hypotensive effects. However, atenolol had little effect while nebivolol significantly ameliorated the functional decline and structural damage in the kidney, especially in non-clipped kidney (NCK), which was associated with the reduction of Ang II in NCK. Moreover, nebivolol inhibited the NCK production of reactive oxygen species (ROS) by decreasing Nox2, Nox4, and p22 expression. Further, nebivolol reduced the plasma and kidney ADMA levels by increasing DDAH2 expression and decreasing PRMT1 expression. Nebivolol also increased the NCK NO level by ameliorating the expression of kidney NOS isoforms. Our results demonstrated that long-term treatment with nebivolol had renoprotective effect in 2K1C rats partly via regulation of kidney ROS-ADMA-NO pathway.</abstract><cop>Switzerland</cop><pmid>32002962</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1734-1140
ispartof Pharmacological reports, 2018-09, Vol.70 (5), p.917
issn 1734-1140
language eng
recordid cdi_pubmed_primary_32002962
source ScienceDirect; Springer Link
subjects Animals
Antihypertensive Agents - pharmacology
Arginine - analogs & derivatives
Arginine - metabolism
Gene Expression Regulation - drug effects
Hypertension - etiology
Isoenzymes
Kidney - drug effects
Kidney Diseases - prevention & control
Male
Nebivolol - pharmacology
Nitric Oxide - metabolism
Nitric Oxide Synthase - genetics
Nitric Oxide Synthase - metabolism
Podocytes - drug effects
Podocytes - pathology
Rats
Rats, Wistar
Reactive Oxygen Species - metabolism
title Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A09%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nephroprotective%20effects%20of%20nebivolol%20in%202K1C%20rats%20through%20regulation%20of%20the%20kidney%20ROS-ADMA-NO%20pathway&rft.jtitle=Pharmacological%20reports&rft.au=Wang,%20Yan&rft.date=2018-09&rft.volume=70&rft.issue=5&rft.spage=917&rft.pages=917-&rft.issn=1734-1140&rft_id=info:doi/&rft_dat=%3Cpubmed%3E32002962%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_320029623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32002962&rfr_iscdi=true